Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs

Esophageal cancer is one of the most lethal human tumors, characterized by relative chemoresistance and poor prognosis. Researchers have been seeking for multimodality to improve its outcome of therapy. PUMA (p53 upregulated modulator of apoptosis) is a potent proapoptotic molecule that is rapidly induced in cells following DNA damage and is required for p53-induced apoptosis. We evaluated the therapeutic potential of PUMA adenovirus against esophageal cancer cell lines (KYSE-150, KYSE-410, KYSE-510 and YES-2). Infection with Ad-PUMA (PUMA Adenovirus) resulted in the more powerful cytotoxicity in these cell lines compared with Ad-p53. Furthermore, we assessed the efficacy of a combined treatment with Ad-PUMA and anticancer drug (cisplatin, paclitaxel, 5-fluorouracil, respectively) for these cells and found PUMA significantly increased the chemosensitivity of esophageal cancer cells, which may result from more abundant apoptosis induction. Interestingly, Ad-PUMA was found to be more efficient than Ad-p53 in inhibiting cell growth and enhancing the chemosensitivity of esophageal cancer cell lines irrespective of the p53 status. These results suggest that Ad-PUMA is a potent cytotoxic agent and could be a promising alternative in the cancer gene therapy in combination with chemotherapeutic agents.

[1]  S. Kyo,et al.  Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. , 2005, Human gene therapy.

[2]  J. Lankelma,et al.  Induction of p53 Up-Regulated Modulator of Apoptosis Messenger RNA by Chemotherapeutic Treatment of Locally Advanced Breast Cancer , 2005, Clinical Cancer Research.

[3]  M. Martinka,et al.  PUMA expression is significantly reduced in human cutaneous melanomas , 2005, Oncogene.

[4]  J. Cleveland,et al.  Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. , 2003, Cancer cell.

[5]  D. Mcfadden,et al.  Differential effects of leptin on cancer in vitro. , 2003, The Journal of surgical research.

[6]  K. Kinzler,et al.  PUMA mediates the apoptotic response to p53 in colorectal cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Jiawei Han,et al.  Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[9]  K. Kinzler,et al.  PUMA induces the rapid apoptosis of colorectal cancer cells. , 2001, Molecular cell.

[10]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[11]  T. Nukiwa,et al.  Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. , 2000, Cancer letters.

[12]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[13]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Irene M. Leigh,et al.  Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer , 1998, Nature.

[15]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[16]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[17]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[18]  Hisashi Tanaka,et al.  Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: Increased frequency and different spectrum of mutations from primary tumors , 1996, International journal of cancer.

[19]  H. Kato.  Diagnosis and Treatment of Esophageal Neoplasms , 1995, Japanese journal of cancer research : Gann.

[20]  D. Fisher.  Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.

[21]  M. Lechner,et al.  Inhibition of p53 DNA binding by human papillomavirus E6 proteins , 1994, Journal of virology.

[22]  P. Sparén,et al.  Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden , 1993, International journal of cancer.

[23]  S. Ohno,et al.  Clinicopathologic study of early stage esophageal carcinoma , 1989, Surgery.

[24]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[25]  Peter D Siersema,et al.  Esophageal cancer. , 2008, Gastroenterology clinics of North America.

[26]  M. Morimatsu,et al.  Expression of G1 cell cycle markers and the effect of adenovirus-mediated overexpression of p21Waf-1 in squamous cell carcinoma of the esophagus. , 2001, International journal of oncology.

[27]  J. Roth,et al.  Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells , 2000, Cancer Gene Therapy.

[28]  K. Cowan,et al.  In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts. , 1999, Oncology research.

[29]  L. Nielsen,et al.  Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer , 1999, Cancer Chemotherapy and Pharmacology.